69 related articles for article (PubMed ID: 17239278)
1. Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.
Pal SK; Hsu J; Hsu S; Hu J; Bergerot P; Carmichael C; Saikia J; Liu X; Lau C; Twardowski P; Figlin RA; Yuh BF
J Geriatr Oncol; 2013 Apr; 4(2):128-33. PubMed ID: 23646100
[TBL] [Abstract][Full Text] [Related]
2. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
[TBL] [Abstract][Full Text] [Related]
3. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Harrop R; Shingler WH; McDonald M; Treasure P; Amato RJ; Hawkins RE; Kaufman HL; de Belin J; Kelleher M; Goonewardena M; Naylor S
Cancer Immunol Immunother; 2011 Jun; 60(6):829-37. PubMed ID: 21387109
[TBL] [Abstract][Full Text] [Related]
4. Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review.
Tayeh GA; Alkassis M; De La Taille A; Vordos D; Champy CM; Pelegrin T; Ingels A
World J Urol; 2024 Jan; 42(1):51. PubMed ID: 38244094
[TBL] [Abstract][Full Text] [Related]
5. Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma.
Wu K; Liu Z; Shao Y; Li X
Front Oncol; 2020; 10():592243. PubMed ID: 33425741
[TBL] [Abstract][Full Text] [Related]
6. Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Stühler V; Bedke J
BMC Med; 2016 Dec; 14(1):201. PubMed ID: 27923360
[TBL] [Abstract][Full Text] [Related]
7. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma.
You D; Lee C; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2331-8. PubMed ID: 27553579
[TBL] [Abstract][Full Text] [Related]
8. Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma.
Bex A
EJC Suppl; 2013 Sep; 11(2):192-203. PubMed ID: 26217128
[No Abstract] [Full Text] [Related]
9. Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?
Husillos Alonso A; Carbonero García M; González Enguita C
World J Nephrol; 2015 May; 4(2):254-62. PubMed ID: 25949939
[TBL] [Abstract][Full Text] [Related]
10. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
Kim DY; Karam JA; Wood CG
World J Urol; 2014 Jun; 32(3):631-42. PubMed ID: 24744223
[TBL] [Abstract][Full Text] [Related]
11. Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Molina AM; Jia X; Feldman DR; Hsieh JJ; Ginsberg MS; Velasco S; Patil S; Motzer RJ
Clin Genitourin Cancer; 2013 Sep; 11(3):297-302. PubMed ID: 23707221
[TBL] [Abstract][Full Text] [Related]
12. Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.
Fisher R; Larkin J; Swanton C
EPMA J; 2011 Dec; 3(1):1. PubMed ID: 22738081
[TBL] [Abstract][Full Text] [Related]
13. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
Karam JA; Rini BI; Varella L; Garcia JA; Dreicer R; Choueiri TK; Jonasch E; Matin SF; Campbell SC; Wood CG; Tannir NM
J Urol; 2011 Feb; 185(2):439-44. PubMed ID: 21167518
[TBL] [Abstract][Full Text] [Related]
14. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
17. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
18. Metastatic renal cell carcinoma: current standards of care.
Thompson JA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():8-12. PubMed ID: 19948454
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era.
Biswas S; Kelly J; Eisen T
Oncologist; 2009 Jan; 14(1):52-9. PubMed ID: 19147692
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
